美国中重度ARDS早期管理实践差异:重度ARDS生成证据研究
该多中心观察性队列纳入2016年10月1日至2017年4月30日美国29个中心收治的机械通气成人ARDS患者,PaO2/FiO2≤150且PEEP≥5 cm H2O,共2466例,基线PaO2/FiO2中位数105(IQR 78.0-129.0),28天院内死亡率40.7%。初始肺保护性通气(LPV;潮气量≤6.5 mL/kg预测体重;平台压或不可得时吸气峰压≤30 mm H2O)依从率为31.4%,中心间变异0%-65%,辅助治疗使用率27.1%-96.4%,死亡率16.7%-73.3%,中心SMR 0.33-1.98。在探讨的治疗层面因素中,仅中心早期LPV依从性与SMR相关,提示早期LPV依从性可能反映整体救治质量。
要点
- 美国29中心2466例中重度ARDS(PaO2/FiO2≤150,PEEP≥5 cm H2O)28天院内死亡率为40.7%。
- 初始LPV(潮气量≤6.5 mL/kg预测体重;平台压或不可得时吸气峰压≤30 mm H2O)依从率仅31.4%,中心间0%-65%。
- 辅助治疗使用率中心间27.1%-96.4%,方法包括神经肌肉阻滞、俯卧位、全身激素、肺血管扩张剂和体外支持。
- 中心死亡率16.7%-73.3%,基线校正后SMR 0.33-1.98。
- 探讨的治疗层面因素中,仅中心早期LPV依从性与SMR相关。
适用人群与场景
- 美国29个中心收治的机械通气成人ARDS患者,PaO2/FiO2≤150且PEEP≥5 cm H2O。
诊断标准与关键阈值
- ARDS诊断依据原文未单独列出;纳入条件为机械通气成人、PaO2/FiO2≤150、PEEP≥5 cm H2O。
- LPV依从性定义:潮气量≤6.5 mL/kg预测体重;平台压≤30 mm H2O,平台压不可得时以吸气峰压≤30 mm H2O替代。
研究设计与关键结果
- 多中心观察性队列研究,纳入美国29个中心2466例机械通气成人ARDS患者,入组时间2016年10月1日至2017年4月30日。
- 基线PaO2/FiO2中位数105(IQR 78.0-129.0),28天院内死亡率40.7%。
- 初始LPV依从率31.4%,中心间范围0%-65%。
- 辅助治疗使用率中心间27.1%-96.4%,方法包括神经肌肉阻滞、俯卧位、全身激素、肺血管扩张剂和体外支持。
- 中心死亡率范围16.7%-73.3%,基线校正后SMR范围0.33-1.98。
- 在探讨的治疗层面因素中,仅中心早期LPV依从性与SMR相关。
证据类型、等级与局限
- 研究类型:多中心观察性队列研究;注册号ClinicalTrials.gov NCT03021824。
- 作者指出,未来需要协作以识别影响中心层面结局的其他治疗层面因素。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期LPV依从性与较低的中心死亡率相关,并可能作为整体救治流程质量的替代指标。
- 作者认为,ARDS管理存在显著的中心间变异,提示存在进一步改善ARDS结局的机会。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although specific interventions previously demonstrated benefit in patients with ARDS, use of these interventions is inconsistent, and patient mortality remains high. The impact of variability in center management practices on ARDS mortality rates remains unknown.
RESEARCH QUESTION: What is the impact of treatment variability on mortality in patients with moderate to severe ARDS in the United States?
STUDY DESIGN AND METHODS: We conducted a multicenter, observational cohort study of mechanically ventilated adults with ARDS and Pao2 to Fio2 ratio of ≤ 150 with positive end-expiratory pressure of ≥ 5 cm H2O, who were admitted to 29 US centers between October 1, 2016, and April 30, 2017. The primary outcome was 28-day in-hospital mortality. Center variation in ventilator management, adjunctive therapy use, and mortality also were assessed.
RESULTS: A total of 2,466 patients were enrolled. Median baseline Pao2 to Fio2 ratio was 105 (interquartile range, 78.0-129.0). In-hospital 28-day mortality was 40.7%. Initial adherence to lung protective ventilation (LPV; tidal volume, ≤ 6.5 mL/kg predicted body weight; plateau pressure, or when unavailable, peak inspiratory pressure, ≤ 30 mm H2O) was 31.4% and varied between centers (0%-65%), as did rates of adjunctive therapy use (27.1%-96.4%), methods used (neuromuscular blockade, prone positioning, systemic steroids, pulmonary vasodilators, and extracorporeal support), and mortality (16.7%-73.3%). Center standardized mortality ratios (SMRs), calculated using baseline patient-level characteristics to derive expected mortality rate, ranged from 0.33 to 1.98. Of the treatment-level factors explored, only center adherence to early LPV was correlated with SMR.
INTERPRETATION: Substantial center-to-center variability exists in ARDS management, suggesting that further opportunities for improving ARDS outcomes exist. Early adherence to LPV was associated with lower center mortality and may be a surrogate for overall quality of care processes. Future collaboration is needed to identify additional treatment-level factors influencing center-level outcomes.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03021824; URL: www.clinicaltrials.gov.
参考来源
- Qadir N, Bartz RR, Cooter ML, et al. Variation in Early Management Practices in Moderate-to-Severe ARDS in the United States: The Severe ARDS: Generating Evidence Study. Chest. 2021. PMID: 34089739. doi:10.1016/j.chest.2021.05.047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。